• Flagship's Cellarity Aims to Advance Cell Behavior-Based Therapeutics

    1 month ago - By Xconomy

    The latest startup to emerge from Flagship Pioneering aims to change drug discovery by starting the process with a clear understanding of cell behavior. Cellarity-like many other startups looking to revamp the slow, costly process of developing new medicines-is using machine-learning tools to do so, leveraging computational advances to advance a new way of thinking about how to treat human illness. Launched in 2017 and backed with $50 million from the Cambridge, MA-based venture capital firm, Flagship general partner and founding Cellarity CEO Avak Kahvejian traces the startup's origins to...
    Read more ...